Author
@ResearchPulse1 ResearchPulse1
grade Bx.com/ResearchPulse1 ↗
Obsessive GLP-1/obesity-drug analyst who reads IQVIA scripts like tea leaves
Tracks the GLP-1/obesity pharma complex in near-real-time, s
trader score
+1.26
hit rate
65%
mean α
+0.90%
signals 14d
112
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Across their last 20 scored bets: 65% hit rate, +0.90% mean alpha, trader score +1.26. Their last-14d mentions, direction-adjusted, have moved +1.9% since posting (mean over 83 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-10-16 | NVO | @ResearchPulse1 | +0.65 | Argues NVO's early CagriSema awareness campaign and branding could support a strong 2027 launch. | +0.6% | tweet ↗ |
| 2026-10-16 | VKTX | @ResearchPulse1 | +0.00 | Argues NVO's early CagriSema awareness campaign and branding could support a strong 2027 launch. | -3.1% | tweet ↗ |
| 2026-10-16 | LLY | @ResearchPulse1 | +0.15 | Argues NVO's early CagriSema awareness campaign and branding could support a strong 2027 launch. | +1.3% | tweet ↗ |
| 2026-10-16 | LLY | @ResearchPulse1 | +0.35 | Expects more Mounjaro users than Zepbound users to switch to Retatrutide after approval. | +1.3% | tweet ↗ |
| 2026-10-15 | LLY | @ResearchPulse1 | +0.65 | Argues Retatrutide and EloraTirz data leave LLY without a meaningful efficacy gap. | +1.7% | tweet ↗ |
| 2026-10-15 | NVO | @ResearchPulse1 | -0.15 | Sarcastically criticizes FDA policy as rewarding premature or grey-market drug launches. | -0.4% | tweet ↗ |
| 2026-10-15 | VKTX | @ResearchPulse1 | -0.15 | Sarcastically criticizes FDA policy as rewarding premature or grey-market drug launches. | -10.9% | tweet ↗ |
| 2026-10-15 | LLY | @ResearchPulse1 | -0.15 | Sarcastically criticizes FDA policy as rewarding premature or grey-market drug launches. | +1.7% | tweet ↗ |
| 2026-10-15 | NVO | @ResearchPulse1 | +0.75 | Denies shorting VKTX and argues CagriSema is materially underestimated by the market. | -0.4% | tweet ↗ |
| 2026-10-15 | VKTX | @ResearchPulse1 | +0.05 | Denies shorting VKTX and argues CagriSema is materially underestimated by the market. | -10.9% | tweet ↗ |
| 2026-10-15 | · | @ResearchPulse1 | · | Acknowledges shorts outperformed longs and expresses surprise at the size of the drop. | · | tweet ↗ |
| 2026-10-15 | VKTX | @ResearchPulse1 | -0.60 | Reports VKTX shorts gaining 40% over three weeks. | -10.9% | tweet ↗ |
| 2026-10-15 | VKTX | @ResearchPulse1 | +0.20 | Notes renewed VKTX shorting, downside risk, and potential biotech buyout activity. | -10.9% | tweet ↗ |
| 2026-10-15 | NVO | @ResearchPulse1 | +0.25 | FDA found serious quality and recordkeeping issues at grey-market API suppliers. | -0.4% | tweet ↗ |
| 2026-10-15 | LLY | @ResearchPulse1 | +0.25 | FDA found serious quality and recordkeeping issues at grey-market API suppliers. | +1.7% | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.